|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Ferlay J, Shin HR, Bray F, et al:
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int
J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tajima Y, Yamazaki K, Makino R, et al:
Gastric and intestinal phenotypic marker expression in early
differentiated-type tumors of the stomach: clinicopathologic
significance and genetic background. Clin Cancer Res. 12:6469–6479.
2006. View Article : Google Scholar
|
|
4
|
Sims GP, Rowe DC, Rietdijk ST, et al:
HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol.
28:367–388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okada H, Imai M, Ono F, et al: Novel
complementary peptides to target molecules. Anticancer Res.
31:2511–2516. 2011.PubMed/NCBI
|
|
6
|
Takahata R, Ono S, Tsujimoto H, et al:
Postoperative serum concentrations of high mobility group box
chromosomal protein-1 correlates to the duration of SIRS and
pulmonary dysfunction following gastrointestinal surgery. J Surg
Res. 170:e135–e140. 2011. View Article : Google Scholar
|
|
7
|
Naglova H and Bucova M: HMGB1 and its
physiological and pathological roles. Bratisl Lek Listy.
113:163–171. 2012.PubMed/NCBI
|
|
8
|
Lee H, Shin N, Song M, et al: Analysis of
nuclear high mobility group box 1 (HMGB1)-binding proteins in colon
cancer cells: clustering with proteins involved in secretion and
extranuclear function. J Proteome Res. 9:4661–4670. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang D, Kang R, Zeh HJ III and Lotze MT:
High-mobility group box 1 and cancer. Biochim Biophys Acta.
1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kostova N, Zlateva S, Ugrinova I and
Pasheva E: The expression of HMGB1 protein and its receptor RAGE in
human malignant tumors. Mol Cell Biochem. 337:251–258. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu D, Ding Y, Wang S, Zhang Q and Liu L:
Increased expression of high mobility group box 1 (HMGB1) is
associated with progression and poor prognosis in human
nasopharyngeal carcinoma. J Pathol. 216:167–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chung HW, Lee SG, Kim H, et al: Serum high
mobility group box-1 (HMGB1) is closely associated with the
clinical and pathologic features of gastric cancer. J Transl Med.
7:382009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Xie C, Zhang X, et al: Elevated
expression of HMGB1 in squamous-cell carcinoma of the head and neck
and its clinical significance. Eur J Cancer. 46:3007–3015. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choi J, Lee MK, Oh KH, et al: Interaction
effect between the receptor for advanced glycation end products
(RAGE) and high-mobility group box-1 (HMGB-1) for the migration of
a squamous cell carcinoma cell line. Tumori. 97:196–202.
2011.PubMed/NCBI
|
|
15
|
Moriwaka Y, Luo Y, Ohmori H, et al: HMGB1
attenuates anti-metastatic defense of the lymph nodes in colorectal
cancer. Pathobiology. 77:17–23. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo Y, Ohmori H, Fujii K, et al: HMGB1
attenuates anti-metastatic defence of the liver in colorectal
cancer. Eur J Cancer. 46:791–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan W, Chang Y, Liang X, et al: High
mobility group box 1 activates caspase-1 and promotes
hepatocellular carcinoma invasiveness and metastases. Hepatology.
55:1863–1875. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tafani M, Schito L, Pellegrini L, et al:
Hypoxia-increased RAGE and P2X7R expression regulates tumor cell
invasion through phosphorylation of Erk1/2 and Akt and nuclear
translocation of NF-{kappa}B. Carcinogenesis. 32:1167–1175.
2011.PubMed/NCBI
|
|
19
|
Chen J, Liu X, Zhang J and Zhao Y:
Targeting HMGB1 inhibits ovarian cancer growth and metastasis by
lentivirus-mediated RNA interference. J Cell Physiol.
227:3629–3638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang W, Wang Z, Li X, et al: Reduced
high-mobility group box 1 expression induced by RNA interference
inhibits the bioactivity of hepatocellular carcinoma cell line
HCCLM3. Dig Dis Sci. 57:92–98. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hanahan D and Weinberg RA: The hallmarks
of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin L, Zhong K, Sun Z, et al: Receptor for
advanced glycation end products (RAGE) partially mediates
HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer
Res Clin Oncol. 138:11–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohmori H, Luo Y and Kuniyasu H:
Non-histone nuclear factor HMGB1 as a therapeutic target in
colorectal cancer. Expert Opin Ther Targets. 15:183–193. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peng RQ, Wu XJ, Ding Y, et al:
Co-expression of nuclear and cytoplasmic HMGB1 is inversely
associated with infiltration of CD45RO+ T cells and
prognosis in patients with stage IIIB colon cancer. BMC Cancer.
10:4962010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wild CA, Brandau S, Lotfi R, et al: HMGB1
is overexpressed in tumor cells and promotes activity of regulatory
T cells in patients with head and neck cancer. Oral Oncol.
48:409–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng BQ, Jia CQ, Liu CT, et al: Serum
high mobility group box chromosomal protein 1 is associated with
clinicopathologic features in patients with hepatocellular
carcinoma. Dig Liver Dis. 40:446–452. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang X, Chavez AR, Schapiro NE, et al:
Ethyl pyruvate administration inhibits hepatic tumor growth. J
Leukoc Biol. 86:599–607. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Czyzewska J, Guzińska-Ustymowicz K, Lebelt
A, et al: Evaluation of proliferating markers Ki-67, PCNA in
gastric cancers. Rocz Akad Med Bialymst. 49(Suppl 1): 64–66.
2004.PubMed/NCBI
|
|
29
|
Cawston TE and Wilson AJ: Understanding
the role of tissue degrading enzymes and their inhibitors in
development and disease. Best Pract Res Clin Rheumatol.
20:983–1002. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Semba S, Moriya T, Kimura W and Yamakawa
M: Phosphorylated Akt/PKB controls cell growth and apoptosis in
intraductal papillary-mucinous tumor and invasive ductal
adenocarcinoma of the pancreas. Pancreas. 26:250–257. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang J, Zhang QY, Fu YC, et al:
Expression of p-Akt and COX-2 in gastric adenocarcinomas and
adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901
gastric adenocarcinoma and U251 glioma cell growth in vitro and in
vivo. Technol Cancer Res Treat. 8:467–478. 2009. View Article : Google Scholar : PubMed/NCBI
|
